Navigation Links
Renal Solutions, Inc. Announces FDA 510(k) Clearance of New Design of the Allient(R) Sorbent Hemodialysis System for Chronic and Acute Hemodialysis
Date:10/22/2007

WARRENDALE, Pa., Oct. 22 /PRNewswire/ -- Renal Solutions, Inc., the exclusive provider of advanced sorbent hemodialysis products and services for treatment of patients with renal failure, announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its newly enhanced Allient(R) Sorbent Hemodialysis System in chronic and acute hemodialysis applications. The new Allient System features improvements in ease of manufacturing, service and user-friendliness. In preparation for the Allient System commercialization, Renal Solutions is also launching its SMARRT(TM) (Sorbent Management for Advanced Renal Replacement Therapy) platform and campaign, which will introduce the benefits of advanced sorbent therapy to the renal community.

SMARRT therapy utilizes a gentle, patient-driven technology backed by over 6 million treatments. It enables short, standard or extended duration hemodialysis therapy using just 1.5 gallons (6 liters) of drinking water. The small dialysate quantity made possible by sorbent technology provides an inherent volume safety not possible with conventional hemodialysis technology. At the same time, it creates a dialysate flow rate of up to 400 ml/min., enabling the provision of highly effective dialysis. Advanced sorbent cartridges contain specialized sorbent compounds that regenerate fresh, high purity dialysate, eliminating the need for complex and costly water purification systems.

The Allient System will be the first dialysis system to bring SMARRT technology to the market, opening new treatment options to dialysis professionals and patients. The Allient System provides multiple treatment options without the need for an independent water purification system, batch production of dialysate, or large volumes of packaged sterile fluid. In addition to the sorbent cartridge benefits, the Allient System's revolutionary Pulsar(TM) Blood Pump provides expanded safety and versatility advantages as compared to conventional pumps. Through its unique, pressure-limited, two-chamber design, the Pulsar Pump enables both dual and single needle access. Pressure limitation, in combination with single needle access, provides added safety against vascular access disconnection, as well as a diminished risk of vascular access trauma.

"Renal Solutions is very excited to introduce the newly designed Allient System and SMARRT Therapy to the hemodialysis market," said Peter M. DeComo, Chairman and CEO of Renal Solutions. "The inherent benefits of a therapy that requires so little water are readily apparent and represent the dialysis technology of the future."

"We're enthusiastic about the options that the Allient System and SMARRT therapy bring to our practice and to the renal world," said Derrick L. Latos, MD, MACP, Medical Director, Wheeling Renal Care, W.V. and Medical Director of Renal Solutions. "The ability to provide flexible treatments in a wide range of treatment environments and the freedom from the hassles of having to provide a complex and expensive water purification system are very attractive benefits to healthcare providers looking to improve the quality of patient care."

About Renal Solutions, Inc

Renal Solutions, Inc., a medical device and healthcare service company, is commercializing the Allient(R) Sorbent Hemodialysis System, a revolutionary technology/service solution for the chronic and acute dialysis market. The Allient System, brings SMARRT (Sorbent Management for Advanced Renal Replacement Therapy) therapy to the dialysis field, opening new treatment options to dialysis professionals and patients by virtue of its ability to provide short, standard or extended duration hemodialysis therapy using just 1 and 1/2 gallons of ordinary drinking water. Numerous clinical studies have shown that an increased cumulative dialysis dose results in better patient outcomes. The Allient System provides the increased dose advantage without the need for an independent water system or large volumes of sterile fluid. This translates into increased flexibility and convenience benefits.

http://www.renalsolutionsinc.com


'/>"/>
SOURCE Renal Solutions, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Renal problem alleviated
2. Increase in renal problems
3. Effect of drug on Renal Cancer
4. Renal problem increased
5. Drug Spironolactone Provides Renal And Cardioprotection In Diabetic Patients
6. Acute Toxicity Of Nano-Scale Zinc Powder: Severe Renal Damage And Anemia
7. A Novel Method Of Detection Of High Nuclear Grade Localized Renal Cell Carcinoma
8. Negative Impact Of Hepatitis C Infection In Renal Transplant Recipients
9. Clinical Renal Trails Do Not Have Sufficient Women Participants
10. Adrenal Suppression not predicted by inhaled corticosteroids
11. Sunitinib a Promising Agent for Treatment of Renal Cell Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... ... announce that Aditya Patel M.D. has joined the revolutionary endoscopic practice under Dr. ... board certification in Interventional Pain Medicine. The patented, revolutionary eDiscSculpt Technique created and ...
(Date:4/28/2017)... ... April 28, 2017 , ... The Texas Cord Blood Bank (TCBB), a ... and delivery team at Women’s Hospital at Renaissance in Edinburg for their outstanding efforts ... hospital and decide to donate. , “Women’s Hospital at Renaissance has been a ...
(Date:4/28/2017)... Yorba Linda, Ca (PRWEB) , ... April 28, ... ... entities with cardiac or hERG liability could substantially improve drug safety and minimize ... will be provided for validating ion channel inhibition using cell lines and for ...
(Date:4/28/2017)... ... ... Bill Howe started his sewer and drain company in 1980 focusing heavily ... team, the Bill Howe brand was born and they began cultivating their mission to ... the San Diego community in which they worked, lived and were raising their daughters. ...
(Date:4/28/2017)... Pensacola, FL (PRWEB) , ... April 28, 2017 ... ... Tampa, Florida are conducting a pilot study of ActiGraph’s CentrePoint Data ... ActiGraph is a leading provider of clinical-grade wearable activity and sleep monitoring solutions ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... -- Research and Markets has announced the addition ... Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and ... ... valued at US$ 7,167.6 Mn in 2015, and is expected ... CAGR of 5.6% from 2016 to 2024. ...
(Date:4/20/2017)... -- Research and Markets has announced the addition ... Analysis By Service (Manufacturing, Research), By Country, (Brazil, Mexico, Colombia, ... report to their offering. ... The Latin American pharmaceutical contract manufacturing services market is ... Low drug registration cost in Latin American countries and continuous ...
(Date:4/19/2017)... The Mobile X-Ray product segment is the most ... the forecast period Mobile X-Ray segment is the ... X-Ray devices market, which is estimated to be valued at ... CAGR of 7% over the forecast period. Mobile X-Ray segment ... US$ 100 Mn in 2017 over 2016. The segment,s revenue ...
Breaking Medicine Technology: